This excerpt taken from the LUX 20-F filed Jun 29, 2005.
Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (FSP FAS 106-2), which supersedes FSP FAS 106-1. Under the Act of 2003, if a sponsor of retiree healthcare plans offers drug benefits that are at least actuarially equivalent to those to be offered under Medicare Part D, it can be entitled to a federal subsidy equal to 28 percent of the prescription drug claims under the plan. FSP FAS 106-2 requires plan sponsors to disclose the effect of the subsidy on the net periodic expense and accumulated post retirement benefit obligation in their interim and annual financial statements for periods beginning after June 15, 2004. The effect of this Act on the Companys current plans was immaterial and thus not disclosed separately due to the small number of eligible plan participants.
In November 2004, the FASB issued SFAS No. 151,